Prenumeration
On December 4th ODI Pharma provided an update regarding Poland’s expanding medical cannabis market. The market remains an important focus of the company’s strategy - recent regulatory changes, where Polish Główny Inspektor Farmaceutyczny (Chief Pharmaceutical Inspectorate or ”GIF”) increased the total amount of medical cannabis permitted to be imported into Poland from 6 tons to approx. 11.3 tons, indicates that the market is one of the fastest-growing and most exciting within medical cannabis in Europe.
Read Analyst Group’s comment here
About Analyst Group: One of Sweden's leading equity research boutiques with focus on small and medium-sized listed companies.
Read more about Analyst Group
This is a press release from Analyst Group regarding the publication of a comment on ODI Pharma. Readers may assume that Analyst Group has received compensation for making the comment. The Company has not been given an opportunity to influence the parts where Analyst Group has had opinions about the Company, future valuation or anything else that could be considered a subjective assessment.